



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Examining Operations

1642
RECEIVED
JUN 16 2003
TECH CENTER 1600/2900

Applicant(s): Ramakrishna et al
Serial No: 10/006,177 Art Unit: Unassigned
Filed: 4 December 2001 Examiner: Unassigned
Title: CYTOTOXIC T-LYMPHOCYTE-INDUCING IMMUNOGENS FOR
PREVENTION, TREATMENT, AND DIAGNOSIS OF CANCER
Docket No: 329755-3

11 June 2003

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Sir:

Applicant herewith submits the following papers:

1. Information Disclosure Statement;
2. Form 1449 plus copies of references; and
3. Return Postcard.

If any fee is due, the Commissioner is authorized to charge any and all such fees to Deposit Account No. 03-0678.

Serial No. 10/006,177
Filed: 4 December 2001

FIRST CLASS CERTIFICATE

I hereby certify that this
correspondence is being deposited
today with the U.S. Postal Service as
First Class Mail in an envelope
addressed to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Alan J. Grant 6/11/03
Alan J. Grant, Esq. Date

Respectfully submitted,

Alan J. Grant

Alan J. Grant, Esq.
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, NJ 07068
Phone: 973-994-1700
Fax: 973-994-1744



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JUN 16 2003
TECH CENTER 1600/2900

Applicant(s): Ramakrishna et al
Serial No: 10/006,177 Art Unit: Unassigned
Filed: 4 December 2001 Examiner: Unassigned
Title: CYTOTOXIC T-LYMPHOCYTE-INDUCING IMMUNOGENS FOR
PREVENTION, TREATMENT, AND DIAGNOSIS OF CANCER
Docket No: 329755-3

11 June 2003

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application. In addition, a supplemental disclosure statement has been filed citing related co-pending applications.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

X §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.

No fee or statement is required.

___§1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

___ The statement as specified in 37 CFR §1.97(e) set out below; OR

___ The fee of \$ 180.00 under 37 CFR §1.17(p).

___§1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND

is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).

___§1.97(e) The undersigned Attorney hereby states that:

___ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;
or

___ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

Serial No: 10/006,177
Filed: 4 December 2001

FIRST CLASS CERTIFICATE

I hereby certify that this
correspondence is being deposited
today with the U.S. Postal Service as
First Class Mail in an envelope
addressed to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450



Alan J. Grant, Esq.

6/11/03
Date

Respectfully submitted,



Alan J. Grant, Esq.
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, NJ 07068
Phone: 973-994-1700
Fax: 973-994-1744

Form PTO-1449

Atty. Docket:
329755-3Serial No.
10/006,177

INFORMATION DISCLOSURE STATEMENT

Applicant: Ramakrishna et al

Filing Date: 4 December 2001

Group:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub- Class	Filing Date
	A1					
	B1					

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Sub- Class	Translation
	C1	WO 93/10814	10 June 1993	PCT		<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	D1					<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

E1	Henderson et al. PNAS. 90:10275-10279 (1993)
F1	Hogan et al, Cancer Research, 58:5144-5150 (1998)
G1	Kinzler et al. Science. 253:661-665 (1991)
H1	Joslyn et al, Cell. 66:601-614 (1991)
I1	Rosenberg et al. Immunity. 10:281-287 (1999)
J1	
K1	
L1	
M1	
N1	

Examiner:

Date Considered:

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.